BidaskClub cut shares of DexCom (NASDAQ:DXCM) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday morning.

DXCM has been the topic of a number of other reports. BMO Capital Markets reaffirmed an outperform rating and issued a $62.00 target price (down from $90.00) on shares of DexCom in a report on Thursday, September 28th. Raymond James Financial cut shares of DexCom from an outperform rating to a mkt perform rating in a report on Friday, September 29th. Canaccord Genuity reaffirmed a buy rating and issued a $69.00 target price (down from $90.00) on shares of DexCom in a report on Thursday, September 28th. TheStreet cut shares of DexCom from a c- rating to a d+ rating in a report on Wednesday, October 25th. Finally, Stephens reaffirmed a buy rating and issued a $70.00 target price (down from $83.00) on shares of DexCom in a report on Thursday, September 28th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $68.50.

Shares of DexCom (NASDAQ:DXCM) traded down $0.23 during trading on Thursday, hitting $56.05. 1,157,253 shares of the stock were exchanged, compared to its average volume of 1,372,633. The firm has a market cap of $4,890.91, a PE ratio of -98.33 and a beta of 0.31. DexCom has a fifty-two week low of $42.62 and a fifty-two week high of $86.32. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, November 1st. The medical device company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. equities analysts expect that DexCom will post -0.65 EPS for the current year.

In related news, Director Steven R. Altman bought 10,000 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were bought at an average cost of $49.61 per share, for a total transaction of $496,100.00. Following the transaction, the director now owns 4,353 shares of the company’s stock, valued at $215,952.33. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the sale, the executive vice president now owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold a total of 48,140 shares of company stock worth $2,727,176 over the last 90 days. Insiders own 1.70% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Inc. boosted its position in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares in the last quarter. Zions Bancorporation boosted its position in shares of DexCom by 36,222.2% in the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after buying an additional 3,260 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of DexCom by 251.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after buying an additional 2,608 shares in the last quarter. CAPROCK Group Inc. purchased a new stake in shares of DexCom in the 4th quarter worth about $224,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after buying an additional 354 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “DexCom (DXCM) Downgraded by BidaskClub” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/20/dexcom-dxcm-downgraded-by-bidaskclub-3.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.